Dr. Ray K. Parker CV

Arkansas, License C-7954

Alpha Omega Alpha Honor Society
Arkansas Foundation for Skin Cancer (Founding Member)
Alen School for Exceptional Children (Board Member)
Baptist Medical Towers (Board Member)
Calvin J. Dillaha Award, Outstanding Senior Student in Dermatology
Omicron Delta Kappa National Honor Society
Beta Beta Beta National Biological Society
Alpha Chi National Scholastic Society
Who’s Who Among American Colleges and Universities
Sigma Chi National Fraternity

American Academy of Dermatology
American Medical Association
Arkansas Medical Society
Pulaski County Medical Society

Parker RK, Dinehart SM, Bennett RG, Houn HY, Fine-Needle Aspiration for Diagnosis of Intranodal Squamous-Cell Carcinoma

Metastic from the skin. Dermatol Sure Oncol 16: 1134-1137, 1990

Mallory SB, Baugh LS, Parker RK Warts in blacks versus whites Pediatr. Dermatol.. 8 (1) 1991.

Parker RK, Mallory SB, Baker GF. Infantile Myofibromatosis. Pediatr Derm & 129-132, 1991

Parker RK Dinehan SM Bennett RG. Houn HY. Fine-Needle Aspiration for Diagnosis of Intranodal Squamous-Cell Carcinoma Metastic from the skin. Year Book Dermatologic Surgery 87-88, 1992.

Parker RK, Crowe MJ, Guin JD. Aquagenic Urticaria Cutis 50: 283-284, 1992

Parker RK, Racque CJ. Eruptive Syringoma. Pediatr Dermatol 3: 91, 1993.

Parker RK, Guin JD. Hand Eczema Herpeticum Cutis 52: 227-228.1993.

Parker RK, Dinehart SM. Hints for Hemostasis. Dermatologic Clinics 12: 601-606, 1994

Parker RK, Lehman PA Franz TJ. Human In Vivo Bioequivalence Assay for Topical Retinoic Acid Formulations. Presented at the American Academy of Dermatology Annual Meeting.
Washington, D>C>: December, 1993. CM Pharm Ther. 184, 1994.

Parker RK, Hope RH, Guin JD. Unusual Nail Discoloration (Hereditary Leukonychia Totalis)
Cosmetic Derm 7: 32-34, 1994.

Dinehart SM, Parker RK, Pappas AA. Acquired Port Wine Stains. Int J Derm.1443-52, 1995.

“Vehicle Controlled Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 2 Days per Week for the Treatment of Actinic Keratoses on the Head.” 2001-2002

“A Phase II Randomized, Placebo-Controlled, Double-Blind Study Of Medi-507, A Humanized Monoclonal Antibody That Binds to the CD-2 Receptor, Administered By Subcutaneous Injection to Adults with Plaque Psoriasis” 2001-2002

“A Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of a Fluconazole Topical Patch in the Treatment of Distal Subungual Onychomycosis of the Great Toenail.” 2001-

“A Phase IIIb, Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of 1.0 mg/kg Subcutaneously Administered Efalizumab In Adults With Moderate To Severe Plaque Psoriasis” 2002-

“A Phase IIIb, An Open Label, Multi-Center Study To Evaluate The Efficacy And Safety of A Subcutaneously Administered Medication, Followed By A Taper Treatment, In Adults With Plaque Psoriasis Previously Enrolled in ACD2390g.” 2002-2003

“A Phase III Multicenter Study of the Safety and Efficacy of an Injectable TNF in Psoriasis”. 2002-2003

“A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study of the Efficacy of an Antifungal Foam vs. an Antifungal Cream in the Treatment of Seborrheic Dermatitis.” 2002 – 2003

“A Randomized Third Party Blind, Multicenter Trial Comparing the Efficacy and Safety of Two Different Antifungals given once daily to Pediatric Patients with Tinea Capitis.” 2002-2003

“A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group Study To Assess The Safety And Tolerability of A New Oral Formulation Of Antifungal Medication In Patients with Onychomycosis Of The Toenails.” 2002 – 2003

“A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate The Safety Of A Subcutaneously Administered Medication In Adults With Moderate To Severe Plaque Psoriasis Who Are Candidates For Systemic Therapy.” 2002-2003

“A Randomized, Double-Blind, Placebo-Controlled, Phase II Dose Ranging Study of an Oral Slow Release Formulation of an Antibiotic as Primary Therapy for Acne Vulgaris in Participants 12-30 Years of Age.” 2002-2003

“A Randomized, Third Party Blind, Multicenter Trial Comparing the Efficacy and Safety of An Anti-fungal Medication Given For 3 Weeks Versus an Antifungal Given for 6 Weeks Versus An Antifungal Given for 6 Weeks Once Daily to Pediatric Patients With Tinea Capitis.”

“An Open Label, Multicenter Trial of an Antifungal for Six Weeks Given Once Daily to Pediatric Patients with Tinea Capitis.”

“A Double Blind, Placebo Controlled, Randomized, Parallel Group Clinical Trial of a subcutaneously administered Human Monoclonal Antibody in Patients with Moderate to Severe Chronic Plaque Psoriasis Vulgaris.” 2002

“An Open Label, Multi-Center Study To Evaluate The Safety Of A Subcutaneously Administered Monoclonal Antibody In Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g.”2003

“A Phase III Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis”

“A Multi-Center Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of a Gel vs. another Gel vs. another Gel vs. Gel Vehicle in the Treatment of Acne Vulgaris”

“A multicentre, randomised, double blind, placebo controlled phase III study of a subcutaneously administered biologic in the treatment and re-treatment of subjects with moderate to severe plaque psoriasis”

“A Phase 3, Multi-Center Study of the Efficacy and Safety of Long-Term Biologic Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis”

“A randomized, investigator blinded, active-controlled, parallel group study to compare the efficacy and safety of 6-week treatment with a new pediatric formula versus 6-week treatment with an approved pediatric suspension in children with Tinea Capitis”

“A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year after Completion of the 1473-IMIQ Study (IND #49,480)”

“A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of a biologic in Subjects with Chronic Plaque Psoriasis Requiring Systemic Therapy”

“An Open-label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis”

“A Randomized, evaluator blinded, vehicle-controlled multi-center study of the safety and efficacy of 4% Tradename Fluorouracil) cream versus its vehicle cream versus Efudex cream in the Treatment of Actinic Keratosis”

“A Phase II, Multi-Center, Randomized, Evaluator-Blind, Vehicle Controlled, 6-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of Clindaben (1/2.5), Clindamycin (1%), and Benzoyl Peroxide (2.5%) Gels in the Treatment of Acne Vulgaris”

“Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis”

“Phase 2/3 Study: A Multicenter Open Label Continuation Study in Moderate to Severe Plaque Psoriasis Subjects who completed a Preceding Psoriasis Clinical Study with Adalimumab”

“A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of 1% and 2% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily in Pediatric and Adolescent Subjects with Mild to Moderate Atopic Dermatitis”

“An Open-Label, Treatment Continuation Study Of 2% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily In Children with Atopic Dermatitis Who Previously Completed A Double-Blind, Placebo-Controlled Study Of NPI 32101”

“A Open-label, multi-center, uncontrolled, single-group assignment, long-term safety study of 4% Tradename (Fluorouracil) cream in subjects with Actinic Keratosis (who participated in the Phase III studies)”

“Observational Post-Marketing Safety Surveillance Registry of Enbrel (entanercept) for the Treatment of Psoriasis”

“A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel vehicle in subjects with acne vulgaris”

“An open-label extension study to evaluate the safety of entercept in pediatric subjects with plaque psoriasis PEDS”

“A phase III, multi-center, randomized, double-blind, vehicle-controlled, 4-arm, parallel group comparison study comparing the efficacy and safety of clindaben 1/2.5), Clindaben vehicle, clindamycin (1%), and benzoyl Peroxide (2.5%) Gels in the treatment of moderate to severe acne vulgaris”

“Pharmacokinetics and Pharmacodynamics of calcitriol following twice daily application of calcitriol 3ug/g ointment under conditions of maximal use in adolescents with plaque psoriasis”

“A Phase 3, multicenter, randomized, double-blind, placebo controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis”

“Raptiva Epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psoriasis”

“A randomized, double-blind, parallel-group, 4-arm, 12-week study to evaluate the safety and efficacy of topically applied CTA018 vs. vehicle for the treatment of adult subjects with chronic plaque psoriasis”

“A Multi-Center Phase 3, Investigator Blind Clinical Trial to Assess the Safety and Efficacy of a Gel, 1% as compared to Gel Vehicle and a Cream, 1% in the Treatment of Rosacea.” 2003

“Vehicle Controlled Double-Blind Study to Assess the Safety and Efficacy of A Topical Cream Applied Once Daily 3 Days per Week in 1 or 2 Courses of Treatment of Actinic Keratoses on the Head.” 2003

“A Follow-up Study to Evaluate Sustained Actinic Keratosis Clearance Rates One Year or More after Completion of the 1444-IMIQ, 1445-IMIQ, 1446-IMIQ, and 1447 IMIQ Studies.” 2003

“A Phase II Study of Two Dosing Schedules of an Anti-TNF subcutaneous injection in Subjects with Moderate to Severe Chronic Plaque Psoriasis. 2003

Amgen Protocol #20030115: An Open Label, Long-Term Extension Study to Assess the Safety of an Anti-TNF subcutaneously injected drug in the Treatment of Psoriasis in Adult Subjects 2003

Dermik Protocol #DL6025-0102: A Double-Blind Placebo Controlled Study of the Recurrence and Re-treatment of Actinic Keratoses after Treatment with a topical cream. 2003

MedImmune Protocol #MI-CPO85; Long Term Safety Follow-Up Study of Psoriasis Patients Who Have Received an Injectable Monoclonal Antibody

Watson Laboratories, Inc. # AF02024: An Open-Label Study of the Safety and Efficacy of a Topical Patch in the Treatment of Distal Subungual Onychomycosis of the Toenails. 2004

Abbott Laboratories Protocol #MO3-596: A Phase II Extension Study of Two Dosing Schedules of an Anti-TNF in Subjects with Moderate to Severe Chronic Plaque Psoriasis. 2003

“A Multi-Center, Open Label, Long-Term Safety Trial of a Topical Gel in the Treatment of Acne Vulgaris”

“Phase III Vehicle-controlled, Double-blind Study to Assess the Safety and Efficacy of a topical cream for the Treatment of Molluscum Contagiosum in Pediatric Patients”

“A Phase II, Multicenter, Double-blind, Randomized, Dose-ranging Evaluation of the Efficacy of a topical Gel Following Repeated Topical Application in Subjects with Acne Vulgaris”

“A randomized, investigator blinded, active-controlled, parallel group study to compare the efficacy and safety of 6-week treatment with a new pediatric formulation versus 6-week treatment with a pediatric suspension in children with Tinea Capitis”

“A Multi Center Open Label Study To Observe the Effect of an anti-TNF monoclonal antibody on Joint and Skin Disease in Subjects with Psoriatic Arthritis”

“A Phase II, Randomized, Double-Blind, Placebo Controlled Study of a Humanized Monoclonal Antibody to Integrin Alpha V Beta, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis”

“A Randomized, Double-Blind, placebo-Controlled Phase III Study of an Extended-Release Formulation of an antibiotic for the Treatment of the Inflammatory Lesions of Acne Vulgaris”

“An Open-Label Safety Study of a New Formulation of an antibiotic for the Treatment of Moderate to Severe Acne”

“A Phase 3, Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of a Foam, in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis”

“A Phase 3, Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of a Foam, in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis”

“A Multicenter, Randomized, Double-Blind, placebo-Controlled Clinical Trial to Determine the Effects of Modified Release Capsules Administered Once Daily for the Treatment of Rosacea”

“Placebo-controlled Multicenter Study with a biologic to Determine Safety and Efficacy in Pediatric Subjects with Plaque Psoriasis (PEDS)”